Third after Pfizer and Modena
EU execution “hope to deliver 400 million times”
viewer
viewer
AstraZeneca’s COVID-19 vaccine has been officially approved for use in Europe. The approval of the corona vaccine is the third after a vaccine developed by Pfizer-Germany Bioentech and Modena.
On the 29th (local time), the European Union (EU) executive committee officially approved the conditional sale of a novel coronavirus infection (Corona 19) vaccine jointly developed by AstraZeneca and Oxford University in the UK.
Executive Chairman Ursula Ponderrayen announced the approval on Twitter that day and said, “We expect AstraZeneca to deliver 400 million batches as agreed.” “We will continue to do everything we can to get a vaccine for Europeans, our neighbors and our partners around the world,” he said.
The EU decision came a few hours after the European Medicines Agency (EMA) recommended conditional marketing approval for the vaccine to targets 18 years of age and older. EMA said that the AstraZeneca vaccine was found to be safe and effective in preventing COVID-19 in people over the age of 18 when the results of clinical trials conducted in the UK, Brazil and South Africa were combined.
However, EMA added that most of the clinical trial participants are 18-55 years of age, and there are no clinical results on the effectiveness of this vaccine on the elderly. However, he added that, according to the precedent of other vaccines, it is expected to be effective for the elderly as well. Earlier, some observations have been made that the EMA may recommend vaccination only to those under the age of 65.
The vaccination committee under the Robert Koch Institute (RKI), a German disease control agency, said that the previous day, the AstraZeneca-Oxford Vaccine did not have sufficient clinical trials for people over 65 years old. Said.
The AstraZeneca vaccine should be given twice, and the interval between 4-12 weeks, EMA believes.
The conditional sale approval first states that it is allowed to sell for only one year. This is a measure to quickly respond to emergencies. Sales approvals must be renewed annually.
The EU previously approved the sale of the COVID-19 vaccine jointly developed by Pfizer and Bioentech on the 21st of last month according to the EMA’s recommendation. On the 27th of last month, the Pfizer-Bioentech vaccination began. It also approved conditional sale of Modena vaccines in the EU earlier this month.
The AstraZeneca vaccine was approved for emergency use in India, Argentina, and Mexico starting in the UK on the 30th of last month.
EMA has said the vaccine has been effective at around 60% in clinical trials, Reuters reported.
The problem is supply. The EU must resolve the issues surrounding pharmaceutical companies and initial supply.
/ Reporter Kim Yeon-ha [email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >